Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

ABSTRACT:

Background and objective

Neoadjuvant chemotherapy (NACT) before radical cystectomy improves outcomes in muscle-invasive bladder cancer (MIBC), but its value before trimodality therapy (TMT; maximal transurethral resection of the bladder tumor plus concurrent chemoradiation) is uncertain. This review aims to evaluate whether the addition of NACT to TMT is associated with improved survival in patients with MIBC.

Methods

We systematically searched the MEDLINE, Embase, and Web of Science databases (February 2025). Eligible studies reported adjusted estimates for overall (OS), cancer-specific (CSS), or disease-free (DFS)/recurrence-free survival in patients undergoing TMT, comparing those who received versus those who did not receive NACT. Random-effect meta-analyses pooled multi

SUBMITTER: Miyajima K 

PROVIDER: S-EPMC12721287 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature